INHIBITORY EFFECT OF CILOSTAZOL ON OSTEOCLAST DIFFERENTIATION BY IN-VITRO AND IN-SILICO STUDIES.

Cilostazol has been reported to reduce the osteoclast differentiation induced in (ApoE-/-) mice model via decreasing the ROS level. To prove this hypothesis 12 wks. old WT and ApoE-/- mice were performed Sham and ovariectomy (OVX) surgery and feed WT mice with normal diet (ND) and ApoE-/- mice model with Atherogenic diet (AD) for 8 Weeks. ApoE-/- mice were injected with I. P injections of Cilostazol (0.5mg/kg) for 8wk. After 8 Wks. Osteoclast differentiation, CROS and bone resorption were analyzed. Cilostazol reduced the osteoclast differentiation and CROS in ApoE-/- mice model with Atherogenic diet (AD). Cilostazol also reduced the bone loss in ApoE-/- mice but the results are not significant as compared to control. Our data highlight the potential role of Cilostazol for attenuating the osteoclast differentiation and bone resorption in ApoE-/- mice model via decreasing the ROS level. The Molecular docking studies between the Cilostazol and RANKL receptors proved that Cilostazol binds tightly to the receptors, showed the highest binding affinities of -7.3, -7.5, -7.7, -8.0, -8.3, and -10.0 kcal/mol. Cilostazol shall be excellent inhibitors against RANKL receptors. [ABSTRACT FROM AUTHOR]